BMY
US EQUITY
Health Care
Pharmaceuticals
CIK: 14272
Bristol Myers Squibb (BMY) Quant Factor Diagnostic & Fair Value Model
Bristol Myers Squibb (Ticker: BMY) is listed in the Health Care sector (Pharmaceuticals). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$61.48
-2.41%
Latest Close (2026-10-23)
Market Cap: $125.59B
P/E Ratio: 9.5
Momentum Strength
3M / 12M
-1.73%
1M: -0.03%
12M: +38.50%
Quality (ROE)
Point-in-Time
+59.45%
Trailing Return on Equity
Technical Trend
RSI 14
58.2
SMA50: $63.20
SMA200: $59.81
Valuation Multiplier
Trailing
9.5
Deep Value (Under 15x P/E)
📊
Valuation & Multi-Factor Diagnostic
Deep Value (Under 15x P/E)
BMY trades at an attractive earnings multiple of 9.5x, significantly lower than the broader S&P 500 average.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 7/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 14272 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-07-30 | $12.97B | $3.32B | $4.50B | $1.62 |
| 10-Q | 2025-12-31 | 2026-07-30 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-07-30 | $12.27B | $1.31B | $5.87B | $0.64 |
| 10-Q | 2026-03-31 | 2026-04-30 | $11.49B | $2.68B | $1.10B | $1.31 |
| 10-Q | 2025-03-31 | 2026-04-30 | $11.20B | $2.46B | $1.95B | $1.20 |
| 10-K | 2025-12-31 | 2026-02-11 | $48.19B | $7.05B | $14.16B | $3.46 |
| 10-K | 2024-12-31 | 2026-02-11 | $48.30B | -$8.95B | $15.19B | $-4.41 |
| 10-K | 2023-12-31 | 2026-02-11 | $45.01B | $8.03B | $13.86B | $3.86 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Bristol Myers Squibb (BMY) valuation multiples, momentum factors, and point-in-time filing conventions.
How should BMY's current valuation multiple be interpreted? ↓
BMY trades at a trailing P/E of 9.5x within the Health Care sector (deep value (under 15x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are BMY's key momentum and technical factor indicators? ↓
As of the latest close, BMY shows a 1-month return of -0.03%, 3-month return of -1.73%, and 12-month return of +38.50%, with a 14-day RSI of 58.2. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for BMY? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can BMY be incorporated into systematic factor models? ↓
BMY can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.